# US Rapid Diagnostics Market > US Rapid Diagnostics Market Research Report: Size, Share, Trend Analysis By Applications (Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy & Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, Toxicology Testing) and By Product Type (Over the Counter (OTC) Kits, Professional Kits) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.98% - **2024:** $ 6.6 Billion - **2025:** $ 7.13 Billion - **2035:** $ 15.37 Billion - **Key Players:** Abbott Laboratories (US), Roche Diagnostics(CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Ortho Clinical Diagnostics (US) **Report ID:** MRFR/MED/15211-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-rapid-diagnostics-market-16739 --- ## Market Summary ## **US Rapid Diagnostics Market Overview** As per MRFR analysis, the US Rapid Diagnostics Market Size was estimated at 4.62 (USD Billion) in 2023. The US Rapid Diagnostics Market Industry is expected to grow from 5.2 (USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The US Rapid Diagnostics Market CAGR (growth rate) is expected to be around 8.3% during the forecast period (2025 - 2035). ### **Key US Rapid Diagnostics Market Trends Highlighted** The US Rapid Diagnostics Market is being shaped by several noteworthy trends that reflect advancements in technology and shifts in healthcare practices. A significant trend is the increasing demand for rapid testing solutions that can provide immediate results, driven by a need for faster clinical decision-making. The COVID-19 pandemic has significantly accelerated the adoption of rapid diagnostics, especially for infectious diseases like influenza and strep throat, fueling interest from both healthcare providers and consumers. This urgent need for timely diagnoses emphasizes the importance of rapid tests in public health systems, showcased by initiatives from the Centers for Disease Control and Prevention (CDC). Key market drivers include the growing awareness about early disease detection and the need for home-based diagnostic solutions, which have been further promoted by healthcare policies aiming to improve accessibility and affordability. Regulatory approvals have streamlined the process for new rapid diagnostic tests, encouraging innovation in product development. Additionally, the push for personalized medicine and point-of-care testing has created opportunities for manufacturers to explore novel methodologies. Emerging opportunities lie in the expansion of rapid diagnostic applications beyond infectious diseases, such as chronic disease management and personalized healthcare. Manufacturers can also capture opportunities by integrating digital health technologies, allowing for better data management and patient engagement. Trends such as increased partnerships between technology firms and healthcare organizations can enhance the reach of rapid diagnostics, supporting advancements in telehealth and remote monitoring. Ultimately, these trends signal a transformative period for the US Rapid Diagnostics Market, aligning with healthcare's broader goals of efficiency and effectiveness in patient care. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Rapid Diagnostics Market Drivers** ### **Increasing Demand for Point-of-Care Testing** The US Rapid Diagnostics Market Industry is experiencing significant growth due to the rising demand for point-of-care testing (POCT). This is largely driven by the need for quick diagnostic results, particularly in emergency and urgent care settings. According to the American Hospital Association, over 36 million emergency department visits reported a need for rapid diagnostic testing, pointing to a consistent growth in POCT needs. Major companies such as Abbott Laboratories and Quidel Corporation are at the forefront of developing innovative POCT solutions, which have greatly enhanced the speed of diagnosis for infectious diseases, chronic conditions, and other medical issues. As more healthcare providers adopt these technologies to improve patient outcomes, the market is expected to thrive. The trend towards decentralization of healthcare services and increased expenditure on healthcare infrastructure are additional factors propelling the growth of the US Rapid Diagnostics Market. ### **Rising Prevalence of Infectious Diseases** The increased incidence of infectious diseases in the US is another important driver for the US Rapid Diagnostics Market Industry. The Centers for Disease Control and Prevention (CDC) have reported a rise in cases of various infectious diseases, including sexually transmitted infections and respiratory ailments, with certain diseases like chlamydia showing a notable 19% increase from 2014 to 2018. This surge has created an urgent need for rapid diagnostic tests to facilitate timely detection and treatment, thereby preventing outbreaks. Companies such as Roche Diagnostics are key players in this domain, actively developing sensitive and rapid testing kits that support healthcare providers in managing infectious disease control efforts. ### **Technological Advancements in Diagnostics** Technological innovation is profoundly influencing the US [**Rapid Diagnostics Market**](../../../reports/rapid-diagnostics-market-11687)Industry. Innovations like microfluidic technology and portable testing devices are significantly enhancing diagnostic precision and usability. The US Food and Drug Administration (FDA) has seen an exponential increase in device approvals, with a reported increase of over 50% in the last five years, setting a conducive environment for rapid diagnostics innovation. Companies including Becton Dickinson and Company and Cepheid are leading the charge in bringing cutting-edge diagnostic technologies to the forefront. This continuous evolution in technology is reducing turnaround times for results and is likely to entice healthcare practitioners toward adopting rapid diagnostics solutions. ### **Government Initiatives and Funding** Government initiatives and funding have emerged as critical drivers for the US Rapid Diagnostics Market Industry. The US government has invested heavily in healthcare and diagnostics, especially in response to the COVID-19 pandemic, with the Health Resources and Services Administration (HRSA) allocating significant funds to enhance access to rapid diagnostic testing services across various communities. Such funding supports the development of robust diagnostic frameworks. As a result, companies like Siemens Healthcare are increasingly involving themselves in collaborative projects funded by the government to bolster rapid testing capabilities across the nation. These initiatives not only improve public health outcomes but also create an environment conducive to market growth and innovation in rapid diagnostics. ## **US Rapid Diagnostics Market Segment Insights** ### **Rapid Diagnostics Market Application Insights** The Application segment of the US Rapid Diagnostics Market plays a crucial role in enhancing healthcare outcomes through timely and accurate testing solutions. This segment includes various applications such as Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy and Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, and Toxicology Testing. Blood Glucose Testing is particularly significant due to the increasing prevalence of diabetes in the US, which necessitates regular monitoring and has created demand for user-friendly and reliable testing devices. Infectious Disease Testing remains a priority, especially in light of global health challenges, driving innovations in point-of-care testing and rapid results that significantly enhance patient management. Cardiometabolic Testing is gaining traction as more emphasis is placed on heart health and the increased incidence of cardiovascular diseases, promoting preventive care and early intervention strategies. Pregnancy and Fertility Testing solutions are critical for family planning, with advancements in at-home testing contributing to their popularity, allowing individuals to track health status with ease. Fecal Occult Blood Testing is vital for early detection of colorectal cancer, influencing screening practices and impacting overall public health initiatives aimed at reducing cancer mortality rates. In addition, Coagulation Testing is essential for monitoring patients on anticoagulants, ensuring safety and efficacy in treatment, while Toxicology Testing plays an increasingly important role in substance abuse screening and workplace health assessments. Overall, these applications represent a dynamic and evolving facet of the US Rapid Diagnostics Market, addressing diverse healthcare needs and contributing to improved patient outcomes through accessible diagnostics. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Rapid Diagnostics Market Product Type Insights** The US Rapid Diagnostics Market exhibits significant growth within its Product Type segment, primarily driven by the increasing demand for efficient and timely diagnostic solutions. Over the Counter (OTC) Kits have emerged as a crucial component in this landscape, enabling consumers to perform tests in the comfort of their homes, thus enhancing accessibility and convenience in healthcare. This trend reflects a growing consumer preference for self-diagnosis and proactive health management. Conversely, Professional Kits, utilized predominantly in clinical settings, remain essential for healthcare professionals who require accurate and rapid test results to inform patient care. These professional solutions often dominate in terms of reliability and comprehensive testing capabilities, catering to a wide spectrum of applications, including infectious diseases and chronic conditions. As a result, the US Rapid Diagnostics Market segmentation highlights diverse opportunities and growth drivers, including technological advancements in testing methodologies, increased public health awareness, and a focus on preventive care. Moreover, the ongoing challenges posed by emerging health threats underscore the necessity for rapid diagnostic solutions in both home and professional environments, thereby strengthening the market's trajectory. ## **US Rapid Diagnostics Market Key Players and Competitive Insights** The US Rapid Diagnostics Market is characterized by a dynamic competitive landscape, driven by a growing demand for quick and reliable diagnostic tests across various healthcare settings. The market has seen significant advancements in technology, with many players developing innovative solutions to improve speed, accuracy, and efficiency in diagnostics. As healthcare systems increasingly prioritize rapid results to enhance patient outcomes, the competition among manufacturers intensifies. Industry leaders are engaged in continuous research and development initiatives, aiming to expand their product portfolios and capitalize on emerging trends such as point-of-care testing and at-home diagnostics. The increasing prevalence of infectious diseases and the recent global health crises have further catalyzed the demand for rapid diagnostic solutions, prompting companies to enhance their capabilities and market reach. Danaher Corporation has established a strong presence in the US Rapid Diagnostics Market, attributed to its diversified portfolio of advanced diagnostics technologies and platforms that cater to various applications. The company's focus on innovation has enabled it to maintain a competitive edge, as it consistently invests in research and development to enhance its offerings. Through strategic collaborations and partnerships, Danaher has expanded its market footprint, allowing it to deliver integrated solutions that meet the evolving needs of healthcare providers. Its commitment to quality and efficiency in product development, along with a strong brand reputation, has positioned Danaher favorably within the competitive landscape. The company's strengths lie in its exceptional technical expertise and ability to adapt to changing market dynamics, ensuring sustained growth and relevance in the rapidly evolving diagnostics sector. Quidel Corporation displays a formidable presence in the US Rapid Diagnostics Market, particularly known for its advancements in point-of-care rapid testing solutions. The company’s portfolio features a range of key products, including rapid immunoassays and molecular diagnostics tailored to infectious disease testing. Quidel's extensive market presence is reinforced by its focus on developing innovative tests that provide quick and accurate results, contributing to timely patient care. The firm has successfully capitalized on opportunities through strategic mergers and acquisitions, enhancing its product offerings and expanding its operational capabilities. Quidel’s strengths include its commitment to high-quality testing solutions, strong distribution networks, and the ability to respond swiftly to public health needs, which has proven particularly vital in addressing outbreaks and urgent health concerns within the US market. Its dedication to research and continuous product innovation positions Quidel as a key player in the competitive landscape of rapid diagnostics. ### **Key Companies in the US Rapid Diagnostics Market Include** ## **US Rapid Diagnostics Market Industry Developments** In recent months, the US Rapid Diagnostics Market has experienced notable advancements and developments. Danaher Corporation has expanded its portfolio by enhancing diagnostic capabilities through strategic partnerships and innovative product launches. Quidel Corporation has introduced new rapid test kits for infectious diseases, reflecting an increasing demand for quick testing solutions post-pandemic. Hologic continues to innovate in women's health diagnostics, while bioMerieux has strengthened its position with new offerings in infectious disease testing. Roche Diagnostics and Abbott Laboratories have also contributed to market growth with novel diagnostic tools. In terms of mergers and acquisitions, BD (Becton, Dickinson and Company) announced its acquisition of a diagnostics company in July 2023, further solidifying its role in the market. Recent financial reports indicate substantial growth in market valuation among leading companies, positively impacting overall industry dynamics. Over the past two to three years, the market has seen significant technological progress and an increasing shift towards decentralized testing solutions, with companies like Cepheid and Thermo Fisher Scientific leading the trend. This evolving landscape is shaping the future of rapid diagnostics, meeting the urgent needs of healthcare providers and patients across the United States. ## **US Rapid Diagnostics Market Segmentation Insights** ### **Rapid Diagnostics Market Application Outlook** ### **Rapid Diagnostics Market Product Type Outlook** ## Market Drivers ### Supportive Regulatory Environment A supportive regulatory environment is crucial for the growth of the rapid diagnostics market. Regulatory bodies in the US are increasingly streamlining the approval processes for diagnostic tests, which facilitates quicker market entry for innovative products. This trend is evident in the FDA's initiatives to expedite the review of diagnostic tools, particularly those that address urgent healthcare needs. The favorable regulatory landscape encourages investment in research and development, fostering innovation within the rapid diagnostics market. As companies navigate the regulatory framework more efficiently, they are better positioned to introduce new and improved diagnostic solutions. This supportive environment is likely to enhance the competitiveness of the rapid diagnostics market, driving growth and expanding access to essential diagnostic services. ### Rising Consumer Awareness and Demand Consumer awareness regarding health and wellness is on the rise, significantly impacting the rapid diagnostics market. As individuals become more informed about their health, there is an increasing demand for accessible and reliable diagnostic tools. This trend is evident in the growing popularity of home testing kits and over-the-counter diagnostic products. The market for home diagnostics is expected to grow at a CAGR of around 12% over the next few years, reflecting the changing consumer preferences. This heightened awareness is driving innovation and competition within the rapid diagnostics market, as companies strive to meet the evolving needs of health-conscious consumers. The emphasis on self-monitoring and preventive care is likely to further propel the growth of the rapid diagnostics market in the coming years. ### Growing Prevalence of Chronic Diseases The rising incidence of chronic diseases in the US is a pivotal driver for the rapid diagnostics market. Conditions such as diabetes, cardiovascular diseases, and infectious diseases necessitate timely diagnosis and management. According to the CDC, approximately 6 in 10 adults in the US have a chronic disease, which underscores the need for efficient diagnostic solutions. Rapid diagnostics enable healthcare providers to make informed decisions quickly, improving patient outcomes. The increasing burden of these diseases is likely to propel the demand for rapid diagnostic tools, as they facilitate early detection and monitoring. This trend indicates a robust growth trajectory for the rapid diagnostics market, as healthcare systems seek to enhance their diagnostic capabilities to address the growing healthcare challenges posed by chronic conditions. ### Increased Focus on Preventive Healthcare The shift towards preventive healthcare is a significant driver for the rapid diagnostics market. As healthcare providers and patients alike recognize the importance of early detection, there is a growing emphasis on screening and monitoring. This trend is supported by initiatives aimed at reducing healthcare costs and improving population health outcomes. The rapid diagnostics market is poised to benefit from this focus, as diagnostic tools play a crucial role in identifying health issues before they escalate. The US healthcare system is increasingly investing in preventive measures, which is likely to enhance the adoption of rapid diagnostic solutions. This proactive approach to health management suggests a promising future for the rapid diagnostics market, as it aligns with the broader goals of improving healthcare efficiency and effectiveness. ### Technological Innovations in Diagnostic Tools Technological advancements are significantly influencing the rapid diagnostics market. Innovations such as point-of-care testing, microfluidics, and artificial intelligence are enhancing the accuracy and speed of diagnostic processes. The integration of these technologies allows for real-time results, which is crucial in clinical settings. For instance, the market for point-of-care testing is projected to reach approximately $50 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 10%. These innovations not only improve diagnostic efficiency but also expand the range of tests available, catering to diverse medical needs. As technology continues to evolve, the rapid diagnostics market is expected to experience substantial growth, driven by the demand for more sophisticated and user-friendly diagnostic solutions. ## Future Outlook The [Rapid Diagnostics Market](https://www.marketresearchfuture.com/reports/rapid-diagnostics-market-11687) is projected to grow at 7.98% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for point-of-care testing, and rising healthcare expenditure. **New opportunities:** - Development of portable diagnostic devices for remote patient monitoring. Integration of AI-driven analytics in diagnostic platforms. Expansion of telehealth services incorporating rapid testing solutions. By 2035, the rapid diagnostics market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product: Over-the-Counter Kits (Largest) vs. Professional Kits (Fastest-Growing) The distribution of the product segment in the US rapid diagnostics market reveals that Over-the-Counter (OTC) Kits currently hold the largest share, appealing to consumers looking for convenient testing options from home. In contrast, Professional Kits are rapidly gaining traction among healthcare providers for their accuracy and reliability in clinical settings. The growth of OTC Kits is driven by increased consumer awareness and accessibility, while the rise of Professional Kits is fueled by advancements in technology and procurement by healthcare institutions. As the healthcare landscape evolves, the demand for both OTC and Professional Kits continues to rise. Factors such as the ongoing emphasis on rapid testing solutions, especially in response to health crises, push the market forward. In particular, the integration of digital technologies into Professional Kits enhances their appeal and effectiveness, marking them as a vital component of clinical diagnostics and ensuring they outpace traditional methods in growth rates. Over-the-Counter Kits (Dominant) vs. Professional Kits (Emerging) Over-the-Counter (OTC) Kits have established themselves as the dominant force in the product segment, primarily because of their convenience and cost-effectiveness for consumers. They enable individuals to conduct tests at home, thus enhancing accessibility to diagnostic solutions. Conversely, Professional Kits are emerging as a critical segment focused on medical facilities seeking reliable and precise diagnostic tools. As healthcare professionals increasingly adopt these advanced kits, their market presence grows, supported by innovations in testing methodologies. These kits cater to a more specialized demographic, addressing the needs of healthcare providers who rely on detailed and accurate results to inform patient care decisions. ### By Application: Blood Glucose Testing (Largest) vs. Infectious Disease Testing (Fastest-Growing) The US rapid diagnostics market exhibits a diversified application segment, with blood glucose testing holding the largest market share. Other applications like infectious disease testing, cardiometabolic testing, pregnancy & fertility testing, fecal occult blood testing, coagulation testing, and toxicology testing contribute to the overall dynamics of this market. Each category has established its niche, reflecting unique consumer needs and technological advances influencing market preferences. Growth trends in the application segment of the US rapid diagnostics market indicate a robust expansion, particularly for infectious disease testing due to rising incidences of infectious conditions and heightened awareness post-pandemic. Blood glucose testing remains indispensable for diabetes management, while innovations in cardiometabolic and toxicology testing further spur market evolution. The demands for rapid and accurate diagnostics continue to drive growth across various applications. Blood Glucose Testing (Dominant) vs. Infectious Disease Testing (Emerging) Blood glucose testing is a dominant force in the US rapid diagnostics market, largely driven by the increasing prevalence of diabetes and the growing need for regular monitoring among patients. This segment benefits from advanced technologies that facilitate quick and reliable results, making it indispensable in both home healthcare and clinical settings. Emerging in contrast, infectious disease testing is rapidly gaining traction, particularly in the wake of recent global health crises. This segment is characterized by its adaptability to new pathogens, enhanced sensitivity, and the integration of molecular diagnostics, positioning it as a critical player in responsive healthcare strategies. Both segments face distinct regulatory challenges and market opportunities that shape their future trajectories. ## Competitive Benchmarking The rapid diagnostics market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for timely and accurate diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing, which allows for rapid results in various settings. Roche Diagnostics (CH) emphasizes its extensive portfolio and integration of digital solutions, enhancing the efficiency of diagnostic processes. Meanwhile, Thermo Fisher Scientific (US) is leveraging strategic partnerships to expand its reach and capabilities in molecular diagnostics, thereby shaping a competitive environment that prioritizes speed and accuracy in diagnostics. In terms of business tactics, companies are increasingly localizing manufacturing to mitigate supply chain disruptions and optimize operational efficiency. The market structure appears moderately fragmented, with several key players exerting influence while also facing competition from emerging firms. This fragmentation allows for diverse offerings, yet the collective strength of established companies like Becton Dickinson and Company (US) and Danaher Corporation (US) plays a crucial role in shaping market dynamics through their extensive distribution networks and established reputations. In October 2025, Roche Diagnostics (CH) announced a significant partnership with a leading [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)provider to integrate its rapid diagnostic tests into remote healthcare services. This strategic move is likely to enhance patient access to diagnostics, particularly in underserved areas, thereby expanding Roche's market footprint and reinforcing its commitment to digital health solutions. The integration of diagnostics with telehealth services may also streamline patient management, indicating a shift towards more holistic healthcare delivery models. In September 2025, Abbott Laboratories (US) launched a new rapid test for infectious diseases that utilizes advanced molecular technology. This innovation not only underscores Abbott's commitment to enhancing diagnostic accuracy but also positions the company to capture a larger share of the growing demand for rapid testing solutions. The introduction of this test is expected to bolster Abbott's competitive edge, particularly in emergency and outpatient settings where rapid results are critical. In August 2025, Thermo Fisher Scientific (US) expanded its manufacturing capabilities by investing in a new facility dedicated to the production of rapid diagnostic kits. This strategic investment is indicative of the company's proactive approach to meeting increasing market demands and ensuring supply chain reliability. By enhancing its production capacity, Thermo Fisher aims to solidify its position as a leader in the rapid diagnostics sector, particularly as healthcare systems continue to prioritize rapid and reliable testing solutions. As of November 2025, the competitive trends in the rapid diagnostics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing innovation and expanding market reach. Looking ahead, competitive differentiation is likely to evolve, with a pronounced shift from price-based competition towards a focus on technological innovation, supply chain reliability, and the ability to deliver rapid, accurate diagnostic solutions. This evolution suggests that companies that prioritize these aspects will be better positioned to thrive in an increasingly competitive landscape. ## Recent News & Developments In recent months, the US Rapid Diagnostics Market has experienced notable advancements and developments. Danaher Corporation has expanded its portfolio by enhancing diagnostic capabilities through strategic partnerships and innovative product launches. Quidel Corporation has introduced new rapid test kits for infectious diseases, reflecting an increasing demand for quick testing solutions post-pandemic. Hologic continues to innovate in women's health diagnostics, while bioMerieux has strengthened its position with new offerings in infectious disease testing. Roche Diagnostics and Abbott Laboratories have also contributed to market growth with novel diagnostic tools. In terms of mergers and acquisitions, BD (Becton, Dickinson and Company) announced its acquisition of a diagnostics company in July 2023, further solidifying its role in the market. Recent financial reports indicate substantial growth in market valuation among leading companies, positively impacting overall industry dynamics. Over the past two to three years, the market has seen significant technological progress and an increasing shift towards decentralized testing solutions, with companies like Cepheid and Thermo Fisher Scientific leading the trend. This evolving landscape is shaping the future of rapid diagnostics, meeting the urgent needs of healthcare providers and patients across the United States. ## Report Scope | MARKET SIZE 2024 | 6.6(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 7.13(USD Billion) | | MARKET SIZE 2035 | 15.37(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.98% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Ortho Clinical Diagnostics (US) | | Segments Covered | Product, Application | | Key Market Opportunities | Integration of artificial intelligence in rapid diagnostics enhances accuracy and efficiency in patient care. | | Key Market Dynamics | Technological advancements drive rapid diagnostics market growth, enhancing accuracy and speed of disease detection. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US rapid diagnostics market in 2024?** A: The market valuation was $6.6 Billion in 2024. **Q: What is the projected market valuation for the US rapid diagnostics market by 2035?** A: The projected valuation for 2035 is $15.37 Billion. **Q: What is the expected CAGR for the US rapid diagnostics market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 7.98%. **Q: Which companies are considered key players in the US rapid diagnostics market?** A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. **Q: What are the two main product segments in the US rapid diagnostics market?** A: The two main product segments are Over-the-Counter (OTC) Kits and Professional Kits. **Q: What was the market size for Over-the-Counter (OTC) Kits in 2024?** A: The market size for Over-the-Counter (OTC) Kits was $2.64 Billion in 2024. **Q: What is the projected market size for Professional Kits by 2035?** A: The projected market size for Professional Kits by 2035 is $9.31 Billion. **Q: Which application segment had the highest market size in 2024?** A: In 2024, the Infectious Disease Testing segment had the highest market size at $2.64 Billion. **Q: What is the projected market size for Blood Glucose Testing by 2035?** A: The projected market size for Blood Glucose Testing by 2035 is $3.05 Billion. **Q: How does the market size for Cardiometabolic Testing compare between 2024 and 2035?** A: The market size for Cardiometabolic Testing is expected to grow from $1.1 Billion in 2024 to $2.5 Billion by 2035. **Q: What is the expected market size of the US Rapid Diagnostics Market in 2024?** A: The US Rapid Diagnostics Market is expected to be valued at 5.2 billion USD in 2024. **Q: What is the projected value of the US Rapid Diagnostics Market by 2035?** A: By 2035, the US Rapid Diagnostics Market is projected to be valued at 12.5 billion USD. **Q: What is the CAGR for the US Rapid Diagnostics Market from 2025 to 2035?** A: The expected CAGR for the US Rapid Diagnostics Market from 2025 to 2035 is 8.3%. **Q: Which application segment is expected to hold the largest market share in 2024?** A: In 2024, the Blood Glucose Testing segment is expected to hold the largest market share valued at 1.4 billion USD. **Q: What market value is projected for the Infectious Disease Testing application by 2035?** A: The Infectious Disease Testing application is projected to have a market value of 3.9 billion USD by 2035. **Q: What is the estimated market value for Cardiometabolic Testing in 2024?** A: The Cardiometabolic Testing segment is estimated to have a market value of 1.2 billion USD in 2024. **Q: How much is the Pregnancy & Fertility Testing application expected to grow by 2035?** A: The Pregnancy & Fertility Testing application is expected to grow to a market value of 1.9 billion USD by 2035. **Q: What are some key growth drivers for the US Rapid Diagnostics Market?** A: Key growth drivers for the US Rapid Diagnostics Market include increasing demand for timely diagnostics and advancements in technology. **Q: What is the projected value for Fecal Occult Blood Testing in 2035?** A: The Fecal Occult Blood Testing application is projected to have a market value of 1.4 billion USD by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-rapid-diagnostics-market-16739*